Aceclofenac
Site-specificity, with state-dependency… the perfect anti-arthritic agent?
New teachings describe the “perfect anti-arthritic agent”; acceptance by KOLs offers unprecedented prospects.
Read the full report
Listing by drug (A-Z)
Amitriptyline
Is refractory cough a neuropathy?
New teachings mean new IP and a new indication for fifty-year old tricyclic anti-depressant.
Read the full report
Azapropazone
Why is the elderly female at high risk for NSAID-induced gastric damage?
New teachings provide robust differentiation that rapidly translates into revenue in a very crowded NSAID market.
Read the full report
Buprenorphine
A new landmark in the treatment of chronic pain
Previously-unknown relationship between ultra-low dose naloxone and buprenorphine fulfills void in pain management.
Read the full report
Buprenorphine
A cardioprotective analgesic for acute MI?
Historical data suggest previously-unknown cardioprotective effects of buprenorphine.
Read the full report
Captopril
Is a thirty-year old drug the new way in managing post MI?
CEME enables powerful differentiation of a thirty-year old drug as ACE inhibitor of choice in the post MI patient.
Read the full report
Captopril
A new era in surgery… scar-free wound healing
McCormack’s methods identify new hope for attaining scar-free wound healing.
Read the full report
Clopidogrel
Has CEME solved the problem of variability in response to clopidogrel?
CEME identifies previously-unknown relationships that provide a new explanation for variability in response to top anti-platelet drug, and new teachings mean new opportunities in emerging markets.
Read the full report
Diclofenac (Intravenous)
Reformulated diclofenac has the potential to target neuropathic pain
New targets for reformulated diclofenac mean that an established drug offers hope to millions of patients with chronic pain.
Read the full report
Divalproex
Using chaos theory to explain how divalproex treats bipolar disorder
CEME identifies chaos theory as a basis for the efficacy of divalproex, and space-filling models confirm that uniquely, divalproex self-assembles.
Read the full report
Donepezil
Using donepezil to diagnose Alzheimer’s disease?
New opportunities for leading Alzheimer drug.
Read the full report
Ketoprofen
Defining a new class of analgesic
CEME identifies novel mechanism of action that differentiates ketoprofen as analgesic of choice in peri-operative pain management. Orudis becomes positioned as blockbuster.
Read the full report
Potassium nitrate (Oral)
New teachings support the use of potassium in managing dentine sensitivity
New teachings mean market leadership through control of the dentine sensitivity market.
Read the full report
Zolpidem
New meta-analysis shows that zolpidem preserves sleep architecture
McCormack’s methods yield dramatic visualization of the novel effects of a leading hypnotic upon sleep architecture.
Read the full report